{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:37:01Z","timestamp":1792622221710,"version":"4.5.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The objectives were to describe treatment sequences for advanced colorectal cancer (CRC), use of second-line FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) plus antiangiogenic drug (bevacizumab, ramucirumab, aflibercept beta) therapy, and the factors associated with the duration of antitumor drug treatment from second-line antiangiogenic therapy in Japan. This retrospective observational study was conducted using a Japanese hospital-based administrative database. Patients were enrolled if they started adjuvant therapy (and presumably experienced early recurrence) or first-line treatment for advanced CRC between May 2016 and July 2019, and were analysed until September 2019. Factors associated with overall treatment duration from second-line treatment with FOLFIRI plus antiangiogenic drugs were explored with multivariate Cox regression analysis. The most common first-line treatments were FOLFOX (leucovorin, 5-fluorouracil, oxaliplatin) or CAPOX (capecitabine, oxaliplatin) with bevacizumab (presumed <jats:italic>RAS<\/jats:italic>-mutant CRC) and FOLFOX with panitumumab (presumed <jats:italic>RAS<\/jats:italic>-wild type CRC). The most common second-line treatments were FOLFIRI-based. Many patients did not transition to subsequent lines of therapy. For second-line treatment, antiangiogenic drugs were prescribed more often for patients with presumed <jats:italic>RAS<\/jats:italic>-mutant CRC, right-sided CRC, and independent activities of daily living (ADL). The median duration of second-line FOLFIRI plus antiangiogenic drug treatment was 4.5 months; 66.2% of patients transitioned to third-line therapy. Low body mass index and not fully independent ADL were significantly associated with shorter overall duration of antitumor drug treatment from second-line therapy. Left-sided CRC, presumed <jats:italic>RAS-<\/jats:italic>wild type CRC, previous use of oral fluoropyrimidines and use of proteinuria qualitative tests, antihypertensives, or anticholinergics during second-line therapy were significantly associated with longer treatment. Treatment of advanced CRC in Japan is consistent with both international and Japanese guidelines, but transition rates to subsequent therapies need improvement. In addition to antitumor drug treatment, better ADL, higher body mass index, management of hypertension, and proteinuria tests were associated with continuation of sequential therapy that included antiangiogenic drugs.<\/jats:p>","DOI":"10.1371\/journal.pone.0246160","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T23:56:45Z","timestamp":1612828605000},"page":"e0246160","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database"],"prefix":"10.1371","volume":"16","author":[{"given":"Eiji","family":"Shinozaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Tanizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhe","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"issue":"6","key":"pone.0246160.ref001","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"F Bray","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"pone.0246160.ref002","unstructured":"Ministry of Health, Labour and Welfare. Overview of the National Cancer Registry 2016. Available from: www.mhlw.go.jp\/content\/10900000\/000468976.pdf."},{"key":"pone.0246160.ref003","unstructured":"Ministry of Health, Labour and Welfare. Cancer Information Service, National Cancer Center, Japan. Cancer Registry and Statistics. Vital Statistics of Japan. Available from: https:\/\/ganjoho.jp\/reg_stat\/statistics\/dl\/index.html#mortality."},{"issue":"1","key":"pone.0246160.ref004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.","volume":"25","author":"Y Hashiguchi","year":"2020","journal-title":"Int J Clin Oncol."},{"issue":"5","key":"pone.0246160.ref005","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","article-title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.","volume":"16","author":"J Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"pone.0246160.ref006","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/cas.13943","article-title":"Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer","volume":"110","author":"T Denda","year":"2019","journal-title":"Cancer Sci"},{"issue":"28","key":"pone.0246160.ref007","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"E Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0246160.ref008","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.soncn.2018.03.008","article-title":"The rise of big data in oncology","volume":"34","author":"KL Fessele","year":"2018","journal-title":"Semin Oncol Nurs"},{"issue":"5","key":"pone.0246160.ref009","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2125.2000.00289.x","article-title":"Design issues for drug epidemiology","volume":"50","author":"AD McMahon","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"pone.0246160.ref010","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/sim.4780100409","article-title":"Channeling bias in the interpretation of drug effects.","volume":"10","author":"H Petri","year":"1991","journal-title":"Stat Med."},{"issue":"2","key":"pone.0246160.ref011","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/sim.4780020222","article-title":"The need for randomization in the study of intended effects.","volume":"2","author":"OS Miettinen","year":"1983","journal-title":"Stat Med."},{"issue":"6 Suppl","key":"pone.0246160.ref012","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1097\/MLR.0b013e3181dbebe3","article-title":"Confounding control in healthcare database research: challenges and potential approaches.","volume":"48","author":"MA Brookhart","year":"2010","journal-title":"Med Care."},{"issue":"1","key":"pone.0246160.ref013","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3820\/jjpe.21.23","article-title":"Utilization of MDV data and data quality control [in Japanese].","volume":"21","author":"M Nakamura","year":"2016","journal-title":"Jpn J Pharmacoepidemiol."},{"issue":"3","key":"pone.0246160.ref014","first-page":"55","article-title":"Development of casemix based evaluation system in Japan.","volume":"4","author":"S Matsuda","year":"2010","journal-title":"Asian Pac J Dis Manag"},{"issue":"1\u20132","key":"pone.0246160.ref015","first-page":"19","article-title":"Clinical epidemiology and health services research using the Diagnosis Procedure Combination database in Japan.","volume":"7","author":"H Yasunaga","year":"2015","journal-title":"Asian Pac J Dis Manag"},{"issue":"1","key":"pone.0246160.ref016","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.2017-0203","article-title":"A comprehensive review of sequencing and combination strategies of targeted agents in metastatic colorectal cancer","volume":"23","author":"KK Ciombor","year":"2018","journal-title":"Oncologist"},{"issue":"2","key":"pone.0246160.ref017","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/09638288809164105","article-title":"The Barthel ADL Index: a standard measure of physical disability?","volume":"10","author":"DT Wade","year":"1988","journal-title":"Int Disabil Stud."},{"issue":"3","key":"pone.0246160.ref018","doi-asserted-by":"crossref","first-page":"370","DOI":"10.6004\/jnccn.2017.0036","article-title":"Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.","volume":"15","author":"AB Benson","year":"2017","journal-title":"J Natl Compr Canc Netw."},{"issue":"8","key":"pone.0246160.ref019","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"E Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"pone.0246160.ref020","doi-asserted-by":"crossref","first-page":"e000135","DOI":"10.1136\/esmoopen-2016-000135","article-title":"S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study.","volume":"2","author":"H Baba","year":"2017","journal-title":"ESMO Open."},{"issue":"3","key":"pone.0246160.ref021","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/annonc\/mdx816","article-title":"S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.","volume":"29","author":"Y Yamada","year":"2018","journal-title":"Ann Oncol."},{"issue":"1","key":"pone.0246160.ref022","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/annonc\/mds289","article-title":"Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer","volume":"24","author":"F Petrelli","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"pone.0246160.ref023","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00280-018-3569-9","article-title":"Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis","volume":"81","author":"S Iizumi","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"pone.0246160.ref024","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/1759-7714.12463","article-title":"Clinical significance of post-progression survival in lung cancer","volume":"8","author":"H Imai","year":"2017","journal-title":"Thorac Cancer"},{"issue":"5","key":"pone.0246160.ref025","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1586\/era.13.37","article-title":"Current opinion on optimal treatment for colorectal cancer","volume":"13","author":"TJ Price","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"pone.0246160.ref026","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.","volume":"25","author":"BJ Giantonio","year":"2007","journal-title":"J Clin Oncol."},{"issue":"5","key":"pone.0246160.ref027","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s10147-018-01391-w","article-title":"Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer","volume":"24","author":"T Yoshihiro","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"pone.0246160.ref028","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00280-012-1948-1","article-title":"The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801).","volume":"70","author":"G Nakayama","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"pone.0246160.ref029","doi-asserted-by":"crossref","first-page":"213","DOI":"10.6004\/jnccn.2012.0020","article-title":"Challenges in the management of older patients with colon cancer","volume":"10","author":"E Dotan","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"pone.0246160.ref030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.","volume":"14","author":"J Bennouna","year":"2013","journal-title":"Lancet Oncol."},{"issue":"9","key":"pone.0246160.ref031","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1093\/annonc\/mdt231","article-title":"Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.","volume":"24","author":"S Kubicka","year":"2013","journal-title":"Ann Oncol."},{"key":"pone.0246160.ref032","first-page":"28","article-title":"VELOUR trial biomarkers update: Impact of RAS, BRAF, and sideness on aflibercept activity [ESMO-GI Abstract LBA005].","author":"P Wirapati","year":"2017","journal-title":"Ann Oncol."},{"issue":"Suppl 1","key":"pone.0246160.ref033","first-page":"S7","article-title":"Current and emerging biomarkers in metastatic colorectal cancer","volume":"26","author":"MKC Lee","year":"2019","journal-title":"Curr Oncol"},{"issue":"2","key":"pone.0246160.ref034","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"OPR Hamnvik","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"pone.0246160.ref035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"H Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"issue":"1","key":"pone.0246160.ref036","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000365156","article-title":"Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials.","volume":"40","author":"RA Lafayette","year":"2014","journal-title":"Am J Nephrol"},{"issue":"6","key":"pone.0246160.ref037","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jdiacomp.2013.07.007","article-title":"Observational research-opportunities and limitations","volume":"27","author":"EJ Boyko","year":"2013","journal-title":"J Diabetes Complications"},{"key":"pone.0246160.ref038","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","article-title":"The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials","volume":"70","author":"JW Holch","year":"2017","journal-title":"Eur J Cancer"},{"issue":"6","key":"pone.0246160.ref039","first-page":"1424","article-title":"Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer: an updated meta-analysis","volume":"10","author":"CJ Zhang","year":"2018","journal-title":"Aging (Albany N Y)."},{"issue":"20","key":"pone.0246160.ref040","doi-asserted-by":"crossref","first-page":"15219","DOI":"10.18632\/oncotarget.24635","article-title":"Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel","volume":"9","author":"N Fukuda","year":"2018","journal-title":"Oncotarget"},{"issue":"32","key":"pone.0246160.ref041","doi-asserted-by":"crossref","first-page":"22332","DOI":"10.18632\/oncotarget.24900","article-title":"Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer","volume":"9","author":"G Roviello","year":"2018","journal-title":"Oncotarget"},{"issue":"6","key":"pone.0246160.ref042","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s11523-019-00683-z","article-title":"Effect of early adverse events on survival outcomes of patients with metastatic colorectal cancer treated with ramucirumab","volume":"14","author":"HH Lim","year":"2019","journal-title":"Target Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T23:57:08Z","timestamp":1612828628000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246160"}},"subtitle":[],"editor":[{"given":"Takeshi","family":"Nagasaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0246160","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]}}}